Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer

Clinical Biochemistry

Volumn 47, Issue 1-2, 2014, Pages 111-116

  Yang, Qi ^a   Shao, Yuan ^a   Shi, Jing ^a   Qu, Yiping ^a   Wu, Kexia ^a   Dang, Siwen ^a   Shi, Bingyin ^a   Hou, Peng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Gastric cancer; Gene methylation; PIK3CA amplification; Poor survival; Quantitative methylation specific PCR (Q MSP)

Indexed keywords

BIOLOGICAL MARKER; DNA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR PAX6; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER;

ADULT; AGED; BASE SEQUENCE; DNA METHYLATION; DNA PRIMERS; EYE PROTEINS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; PAIRED BOX TRANSCRIPTION FACTORS; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84890559580     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.10.014     Document Type: Article

References (35)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Akoh J.A., Macintyre I.M. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 1992, 79:293-299.
3. Hundahl S.A., Phillips J.L., Menck H.R. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000, 88:921-932.
4. Yasui W., Oue N., Kuniyasu H., Ito R., Tahara E., Yokozaki H. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 2001, 4:113-121.
5. Yokozaki H., Yasui W., Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol 2001, 204:49-95.
6. Michl P., Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol 2005, 43:113-119.
7. Yu H.G., Ai Y.W., Yu L.L., Zhou X.D., Liu J., Li J.H., et al. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 2008, 122:433-443.
8. Qu J.L., Qu X.J., Zhao M.F., Teng Y.E., Zhang Y., Hou K.Z., et al. Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and MAPK/ERK activation. Dig Liver Dis 2009, 41:875-880.
9. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
10. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24:1477-1480.
11. Garcia-Rostan G., Costa A.M., Pereira-Castro I., Salvatore G., Hernandez R., Hermsem M.J., et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005, 65:10199-10207.
12. Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G., Schwartz S., et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005, 41:1649-1654.
13. Barbi S., Cataldo I., De Manzoni G., Bersani S., Lamba S., Mattuzzi S., et al. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 2010, 29:32.
14. Corso G., Velho S., Paredes J., Pedrazzani C., Martins D., Milanezi F., et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 2011, 47:443-451.
15. Shi J., Yao D., Liu W., Wang N., Lv H., Zhang G., et al. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 2012, 12:50.
16. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999, 21:99-102.
17. Ma Y.Y., Wei S.J., Lin Y.C., Lung J.C., Chang T.C., Whang-Peng J., et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000, 19:2739-2744.
18. Hou P., Liu D., Shan Y., Hu S., Studeman K., Condouris S., et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007, 13:1161-1170.
19. Yao D., Shi J., Shi B., Wang N., Liu W., Zhang G., et al. Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta 2012, 413:787-794.
20. Qu Y., Dang S., Hou P. Gene methylation in gastric cancer. Clin Chim Acta 2013, 424C:53-65.
21. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
22. Ji M., Guan H., Gao C., Shi B., Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011, 11:147.
23. Wu G., Mambo E., Guo Z., Hu S., Huang X., Gollin S.M., et al. Uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 2005, 90:4688-4693.
24. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
25. Hu S., Liu D., Tufano R.P., Carson K.A., Rosenbaum E., Cohen Y., et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and braf mutation in papillary thyroid cancer. Int J Cancer 2006, 119:2322-2329.
26. Shi J., Zhang G., Yao D., Liu W., Wang N., Ji M., et al. Prognostic significance of aberrant gene methylation in gastric cancer. Am J Cancer Res 2012, 2:116-129.
27. Gray J.W., Collins C. Genome changes and gene expression in human solid tumors. Carcinogenesis 2000, 21:443-452.
28. Buffart T.E., Carvalho B., Mons T., Reis R.M., Moutinho C., Silva P., et al. DNA copy number profiles of gastric cancer precursor lesions. BMC Genomics 2007, 8:345.
29. Tsukamoto Y., Uchida T., Karnan S., Noguchi T., Nguyen L.T., Tanigawa M., et al. Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer. J Pathol 2008, 216:471-482.
30. Dammann R., Li C., Yoon J.H., Chin P.L., Bates S., Pfeifer G.P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000, 25:315-319.
31. Ben Ayed-Guerfali D., Benhaj K., Khabir A., Abid M., Bayrouti M.I., Sellami-Boudawara T., et al. Hypermethylation of tumor-related genes in tunisian patients with gastric carcinoma: clinical and biological significance. J Surg Oncol 2011, 103:687-694.
32. Agathanggelou A., Cooper W.N., Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005, 65:3497-3508.
33. Zhou Y.H., Wu X., Tan F., Shi Y.X., Glass T., Liu T.J., et al. PAX6 suppresses growth of human glioblastoma cells. J Neurooncol 2005, 71:223-229.
34. Robson E.J., He S.J., Eccles M.R. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006, 6:52-62.
35. Shyr C.R., Tsai M.Y., Yeh S., Kang H.Y., Chang Y.C., Wong P.L., et al. Tumor suppressor PAX6 functions as androgen receptor co-repressor to inhibit prostate cancer growth. Prostate 2010, 70:190-199.